eazy
Well-known member
Pepetide Retatrutide
Retatrutide is a triple receptor agonist developed by Eli Lilly. It acts on GLP1, GIP, and glucagon receptors, which gives it unique metabolic effects. Unlike existing drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro), which target fewer pathways.
Retatrutide combines appetite suppression, improved insulin sensitivity, and increased energy expenditure through glucagon activation.
Clinical trials show impressive results, as participants experienced up to 24.2% body weight loss after 48 weeks, with improvements in blood sugar, liver fat, triglycerides, and blood pressure.
The most common side effects were mild gastrointestinal issues such as nausea or constipation.
Bodybuilders and others in fitness communities are paying attention because retatrutide’s combination of fat-burning and muscle preserving mechanisms which could theoretically support contest preparation.
However, these uses remain speculative since trials have focused on obesity and metabolic disease, not athletic populations.
Retatrutide is said to not be FDA approved and may not be available until 2028. Odd… as people have their hands on it now. lol
Here’s a comparison with Ozempic and Tirzepatide:
Ozempic (semaglutide) acts only on GLP1 receptors.
It reduces appetite and improves insulin response but does not significantly increase energy expenditure. Average long term weight loss is around 10-15% of body weight.
Tirzepatide (Mounjaro) targets both GLP1 and GIP receptors.
It produces greater weight loss than Ozempic, up to 20% of body weight in trials, and also improves blood sugar control.
Retatrutide adds glucagon receptor activation on top of GLP1 and GIP. This third pathway drives higher fat oxidation and energy use, resulting in up to 24% weight loss and potentially greater muscle preservation.
In summary, retatrutide shows dramatic fat loss potential and metabolic benefits that surpass both Ozempic and Tirzepatide.
In stock at us-pharmacies.com
Retatrutide is a triple receptor agonist developed by Eli Lilly. It acts on GLP1, GIP, and glucagon receptors, which gives it unique metabolic effects. Unlike existing drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro), which target fewer pathways.
Retatrutide combines appetite suppression, improved insulin sensitivity, and increased energy expenditure through glucagon activation.
Clinical trials show impressive results, as participants experienced up to 24.2% body weight loss after 48 weeks, with improvements in blood sugar, liver fat, triglycerides, and blood pressure.
The most common side effects were mild gastrointestinal issues such as nausea or constipation.
Bodybuilders and others in fitness communities are paying attention because retatrutide’s combination of fat-burning and muscle preserving mechanisms which could theoretically support contest preparation.
However, these uses remain speculative since trials have focused on obesity and metabolic disease, not athletic populations.
Retatrutide is said to not be FDA approved and may not be available until 2028. Odd… as people have their hands on it now. lol
Here’s a comparison with Ozempic and Tirzepatide:
Ozempic (semaglutide) acts only on GLP1 receptors.
It reduces appetite and improves insulin response but does not significantly increase energy expenditure. Average long term weight loss is around 10-15% of body weight.
Tirzepatide (Mounjaro) targets both GLP1 and GIP receptors.
It produces greater weight loss than Ozempic, up to 20% of body weight in trials, and also improves blood sugar control.
Retatrutide adds glucagon receptor activation on top of GLP1 and GIP. This third pathway drives higher fat oxidation and energy use, resulting in up to 24% weight loss and potentially greater muscle preservation.
In summary, retatrutide shows dramatic fat loss potential and metabolic benefits that surpass both Ozempic and Tirzepatide.
BY: RawCutlery IFBB Pro
In stock at us-pharmacies.com
